The continuing Russia-Ukraine war and associated disruption is expected to funnel more clinical studies to the Asia-Pacific (APAC), a region that’s seeing an uptick in trials and is a growing base of cutting-edge pharma R&D.
Parexel Execs On Global Adjustments In The Trial Site Landscape
APAC Emerges Amid Global Challenges
Senior Parexel executives tell Scrip that disruptions resulting from the Ukraine war and constraints in the US given the backlog in clinical care there could channel more trials to the Asia-Pacific region. They also discuss how things are moving in China, a market where the CRO has long-standing experience, the "conducive" ecosystem in India and issues around trial diversity.

More from R&D
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
More from Scrip
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.